gankyrin Antibody (G-2): sc-166213

gankyrin Antibody (G-2) is a mouse monoclonal IgG2a antibody that detects gankyrin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Gankyrin plays a crucial role in regulating protein-protein interactions that are essential for cell cycle control and protein degradation, making gankyrin a significant factor in the progression of hepatocellular carcinoma. Gankyrin is primarily located in the cytoplasm and nucleus of cells, where gankyrin facilitates the assembly of multiprotein complexes that are vital for cellular functions. Gankyrin′s presence in these cellular compartments underscores gankyrin′s importance in maintaining cellular homeostasis and regulating the cell cycle, as aberrations in these processes can lead to tumorigenesis. Gankyrin contains six ankyrin repeat domains, which are critical for gankyrin′s interactions with key regulatory proteins such as retinoblastoma protein (Rb), cyclin-dependent kinase 4 (Cdk4), and the 26S proteasome. Notably, gankyrin′s interaction with MAGE-A4 has been shown to suppress anchorage-independent growth in cells that overexpress gankyrin, highlighting gankyrin′s potential as a target for immunotherapy in hepatocellular carcinoma. anti-gankyrin antibody (G-2) is an invaluable tool for researchers investigating the molecular mechanisms underlying cancer progression and the therapeutic potential of targeting gankyrin in various malignancies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

gankyrin Antibody (G-2) References:

1. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.  |  Zheng, T., et al. 2014. Hepatology. 59: 935-46. PMID: 24037855
2. Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma.  |  Zamani, P., et al. 2018. Artif Cells Nanomed Biotechnol. 46: 1301-1313. PMID: 29025272
3. Gankyrin as a potential target for tumor therapy: evidence and perspectives.  |  Li, H., et al. 2018. Am J Transl Res. 10: 1949-1960. PMID: 30093934
4. The Oncoprotein Gankyrin/PSMD10 as a Target of Cancer Therapy.  |  Fujita, J. and Sakurai, T. 2019. Adv Exp Med Biol. 1164: 63-71. PMID: 31576540
5. Gankyrin promotes osteosarcoma tumorigenesis by forming a positive feedback loop with YAP.  |  Cheng, L., et al. 2020. Cell Signal. 65: 109460. PMID: 31678253
6. Gankyrin activates the hedgehog signalling to drive metastasis in osteosarcoma.  |  Wang, C., et al. 2021. J Cell Mol Med. 25: 6232-41. PMID: 34089292
7. Gankyrin has a potential role in embryo implantation via activation of STAT3.  |  Yu, M., et al. 2022. Reproduction. 163: 157-165. PMID: 35038312
8. Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.  |  Kanabar, D., et al. 2022. J Med Chem. 65: 8975-8997. PMID: 35758870
9. Gankyrin modulated non-small cell lung cancer progression via glycolysis metabolism in a YAP1-dependent manner.  |  Yu, T., et al. 2022. Cell Death Discov. 8: 312. PMID: 35810157
10. Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance.  |  Peng, G., et al. 2023. Oncoimmunology. 12: 2173422. PMID: 36776524

The preferred gankyrin antibody is gankyrin Antibody (3A6C2): sc-101498.